VEGFA and choroidal neovascularization: Bevacizumab, a full-length, humanized, anti- vascular endothelial growth factor (VEGF) monoclonal antibody has shown promising success in the treatment of age-related macular degeneration, choroidal neovascularization and proliferative diabetic retinopathy [1-3].